_1698905870 20231102061750000 Rovedar Daryoushbabazadeh@gmail.com Rovedar Journal of Lab Animal Research J Lab Anim. Res 2980-9703 10 25 2023 2 5 Mahdiyeh Rahdari https://orcid.org/0009-0005-5646-6082 Homa Sadat Hashemi https://orcid.org/0009-0002-5407-0218 Seyed Mohamad Ali Hashemi https://orcid.org/0000-0001-6731-9110 Ali Nadjafi-Semnani https://orcid.org/0000-0002-8801-2588 Saeid Jamalie https://orcid.org/0000-0002-0587-1644 Mohammad Hossein Sakhaee https://orcid.org/0000-0001-8255-8320 Fariba Zabihi https://orcid.org/0000-0001-5034-9356 Seyed Ali Shariat Razavi https://orcid.org/0000-0001-7535-7838 Masoumeh Taghdisi Khaboushan https://orcid.org/0009-0002-2941-6459 Ghazale Ahmadi https://orcid.org/0000-0002-7480-2589 Breast cancer continues to pose a significant threat to women’s health around the globe, requiring continuous research and innovation in treatment. In recent years, metal nanoparticles have emerged as a promising means of treating breast cancer with greater precision and efficiency. The in vivo studies have indicated that metal nanoparticles, such as gold, silver, and platinum, have demonstrated a remarkable ability to selectively target breast cancer cells while sparing healthy tissue. These nanoparticles’ size, shape, and surface chemistry can be altered to enhance their biocompatibility, stability, and drug-loading capacity. They are also highly versatile for therapeutic applications due to their unique physicochemical properties, such as drug delivery, photothermal therapy, and imaging. This review focuses on recent in vivo studies evaluating metal nanoparticles’ safety and efficacy in treating breast cancer. Several studies have demonstrated that metal nanoparticles can trigger apoptosis, inhibit tumor growth, and reduce metastasis in cancer cells. Furthermore, using these nanoparticles with traditional chemotherapy and radiotherapy has demonstrated a synergistic effect, enhancing treatment efficacy. This review also examines the challenges and concerns associated with the clinical translation of metal nanoparticles. Factors like biocompatibility, pharmacokinetics, and long-term safety profiles are discussed in the context of regulatory approval and patient-specific considerations. In conclusion, this review highlights the evolving landscape of breast cancer treatment with the development of metal nanoparticles, as evidenced by recent in vivo studies. In addition to their therapeutic versatility, these nanoparticles can potentially improve patient outcomes and decrease the burden of breast cancer on society. 10 25 2023 63 71 https://creativecommons.org/licenses/by/4.0 10.58803/jlar.v2i5.31 https://jlar.rovedar.com/index.php/JLAR/article/view/31 https://jlar.rovedar.com/index.php/JLAR/article/download/31/56 https://jlar.rovedar.com/index.php/JLAR/article/download/31/56 10.1186/s12943-023-01805-y 10.1166/jctn.2020.8924 10.1038/s41572-019-0111-2 10.2174/1871520623666230529141544 10.2174/1573394719666230427094247 10.7314/APJCP.2016.17.S3.43 10.1371/journal.pone.0257680 10.1016/j.tjog.2020.01.010 10.1002/vms3.1221 10.1038/s41568-019-0186-9 10.1016/j.jddst.2021.102487 10.1007/s42247-021-00335-x 10.3390/ma16155354 10.1016/j.phrs.2016.03.002 10.1039/c2cs15355f 10.1021/acs.chemrev.0c00779 10.1016/j.eurpolymj.2019.109371 10.1080/17425247.2021.1888926 10.3390/molecules26216532 10.1016/j.ijpharm.2018.10.048 10.1021/acsanm.1c00987 10.1186/s40580-019-0193-2 10.1021/cr400295a 10.1016/j.addr.2013.11.009 10.1038/nrc.2016.108 10.1146/annurev-bioeng-112315-031200 10.1016/j.biomaterials.2016.06.007 10.1126/science.1226338 10.1002/cctc.201200229 10.1016/j.jddst.2019.101174 10.1039/C5GC02500A 10.1002/smll.202007073 10.1155/2020/5194780 10.1517/17425247.2010.498473 10.1002/wnan.1304 10.1039/D0TB00739K 10.1016/j.biopha.2022.112951 10.2147/IJN.S36111 10.3390/polym13111717 10.1002/anie.201403036 10.3390/jfb13040196 10.3390/nano10112186 10.1146/annurev-bioeng-071811-150124 10.1021/acs.jpcc.9b00913 10.1016/j.phrs.2010.03.005 10.1016/j.semcancer.2019.11.002 10.1021/acs.jmedchem.9b00511 10.1016/j.jconrel.2020.04.010 10.1021/ar2000277 10.1038/aps.2011.82 10.3390/ijms21072536 10.1002/wnan.1322 10.1155/2018/4924186 10.3390/ijms21072480 10.1021/acs.molpharmaceut.8b00810 10.2147/NSA.S3788 10.1007/s10876-020-01955-9 10.1016/j.jconrel.2021.05.012 10.1186/s11671-021-03628-6 10.1016/j.jconrel.2012.12.013 10.1016/j.nano.2013.07.001 10.3390/ma13020279 10.1016/j.ccr.2019.02.025 10.3389/fchem.2019.00167 10.1016/j.jphotobiol.2020.111902 10.1016/j.msec.2016.03.101 10.1155/2013/535796 10.1038/s41598-017-11121-3 10.2174/1871520619666190710121727 10.1080/21691401.2016.1202257 10.1016/j.jcis.2020.02.051 10.1039/D1RA03133C 10.1021/acs.molpharmaceut.9b01318 10.1039/C8NR07769J 10.3389/fphar.2022.797804 10.1021/acsanm.0c02521 10.1002/ppsc.202100115 10.1039/D3NR00221G 10.1039/C8NJ03350A 10.3390/ma14123155 10.1021/acsami.5b04548 10.1021/nl802915q 10.1016/j.biomaterials.2019.01.001 10.1039/C5RA08110F 10.1096/fba.2019-00021 10.1016/j.ijpharm.2020.119729 10.1016/j.mtcomm.2020.102001 10.1021/acsami.6b12792 10.7150/thno.64511 10.2147/IJN.S288236 10.1016/j.semcancer.2019.10.020 10.1016/j.jconrel.2022.11.009 Nikdouz A, Namarvari N, Shayan RG and Hosseini A. Comprehensive comparison of theranostic nanoparticles in breast cancer. Am J Clin Exp Immunol. 2022; 11(1): 10.1007/978-3-030-40513-7_56 10.1166/jnn.2016.11774 10.1038/nnano.2007.223 10.1002/wnan.103 10.1007/s10311-020-01033-6 10.1002/jat.3499 10.1016/j.drudis.2015.05.009 10.1016/j.impact.2020.100253 10.1021/jp806073t 10.2217/nnm.11.79 10.1002/adma.201704307 10.1002/tcr.202100331 10.3389/fmolb.2014.00015 10.1039/C5TB00841G